Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.54 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.54 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25698182 | 1.00 | PTGS1 (0.54) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| SCHEMBL11591641 | 1.00 | PTGS1 (0.54) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| SCHEMBL8417619 | 0.98 | PTGS1 (0.55) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| SCHEMBL8414647 | 0.98 | PTGS1 (0.55) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| SCHEMBL8417618 | 0.98 | PTGS1 (0.55) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| SCHEMBL8414650 | 0.98 | PTGS1 (0.55) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| SCHEMBL8414651 | 0.98 | PTGS1 (0.55) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| Cyclohexanol SCHEMBL8424527 | 0.95 | PTGS1 (0.50) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| SCHEMBL16766407 | 0.94 | PTGS1 (0.59) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 | |
| SCHEMBL25698143 | 0.94 | PTGS1 (0.59) | PTGS1PTGS2MT-CO1MT-CO2SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | ATM, CHEK2, CHEK1 | PTGS1 3244/4885PTGS2 3421/4885MT-CO1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.